The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Davide Melisi
Consulting or Advisory Role - Incyte; iOnctura; SERVIER; Taiho Pharmaceutical; TERUMO
Research Funding - iOnctura
 
Alberto Quinzii
No Relationships to Disclose
 
Monica Valente
Consulting or Advisory Role - Novartis
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Immunocore; Immunocore; MSD Oncology; Pierre Fabre; Sanofi; Sun Pharma
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Giovanni Amato
No Relationships to Disclose
 
Elena Simonetti
No Relationships to Disclose
 
Camilla Zecchetto
No Relationships to Disclose
 
Simona Casallino
No Relationships to Disclose
 
Luigi Leta
No Relationships to Disclose
 
Luisa Messineo
No Relationships to Disclose
 
Lucia Mendo
No Relationships to Disclose
 
Tracey Hammett
Employment - iOnctura
Stock and Other Ownership Interests - iOnctura
 
Marcel Deken
No Relationships to Disclose
 
Giusy Di Conza
No Relationships to Disclose
 
Paramjit Kaur
Employment - AstraZeneca; iOnctura
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - iOnctura
 
Michael M. F. Lahn
Employment - iOnctura
Leadership - iOnctura
Stock and Other Ownership Interests - Incyte; iOnctura
 
Michele Maio
Stock and Other Ownership Interests - Epigen Therapeutics; Theravance
Honoraria - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck; MSD; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Alfasigma; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche
Patents, Royalties, Other Intellectual Property - DNA Hypomethylating agents for cancer therapy
Travel, Accommodations, Expenses - Alfasigma; Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pierre Fabre; Roche